NewLimit
NewLimit is a longevity startup based in South San Francisco. It aims to extend human healthspan by reversing the aging process at the cellular level. The company plans its first clinical trial, of a liver medicine.
Leadership
Jacob Kimmel, Co-founder and CEO. Jacob Kimmel is co-founder and CEO of NewLimit, a longevity startup based in South San Francisco.
Who it reaches
Its first planned clinical trial is for a liver medicine.
Key facts
WYDE coverage of NewLimit
WYDE Newsroom has published 2 articles about NewLimit, from Jun 23, 2026 to Jul 14, 2026. NewLimit is the subject of 2 stories. The most recent is Life Biosciences Doses the First Patient as Cellular Rejuvenation Reaches Human Trials.
Life Biosciences Doses the First Patient as Cellular Rejuvenation Reaches Human Trials
Life Biosciences dosed the first patient in its ER-100 partial epigenetic reprogramming trial and NewLimit raised $435 million for its own first human trial, moving cellular rejuvenation and longevity science from mice into people in 2026.
Jul 14, 2026 · 2 min read · Subject of the story
Crypto & DeFiCoinbase CEO's Longevity Startup NewLimit Raises $435 Million at $3.1 Billion Valuation
NewLimit, the cell-reprogramming startup co-founded by Coinbase CEO Brian Armstrong, raised a $435 million Series C led by Founders Fund, tripling its valuation.
Jun 23, 2026 · 2 min read · Subject of the story
Reported alongside NewLimit
- Brian Armstrong · in 2 stories with NewLimit
- Life Biosciences · in 1 story with NewLimit
- Jacob Kimmel · in 1 story with NewLimit
Sources
Track the institutions that move money.
Data-driven coverage, every week.